These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30890066)

  • 21. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
    Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
    Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in chimeric antigen receptor T cells.
    Beyar-Katz O; Gill S
    Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
    Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
    Al-Juhaishi T; Ahmed S
    Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
    Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
    Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reporting data of patients receiving CAR T cell therapy into the EBMT registry: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Vasseur A; Karam M; Chaillou D; Colonnese E; Dantin C; Latiere C; Meziane Y; Pereira M; Yakoub-Agha I; Chabannon C; Raus N
    Bull Cancer; 2020 Dec; 107(12S):S178-S184. PubMed ID: 31831153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Gauthier J
    Bull Cancer; 2018 Dec; 105 Suppl 2():S214-S217. PubMed ID: 30686360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
    Liu Y; Chen X; Han W; Zhang Y
    Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
    Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
    Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.
    Pantin J; Battiwalla M
    Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
    Talleur AC; Myers R; Annesley C; Shalabi H
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.